Who are Intranasal Paracetamol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Preop acetaminophen IV, Panadol®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intranasal-paracetamol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Intranasal Paracetamol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intranasal Paracetamol (Intranasal Paracetamol) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Analgesic and antipyretic (non-NSAID). Area: Pain Management.

phase 3 Analgesic and antipyretic (non-NSAID) Cyclooxygenase (COX) enzymes Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Intranasal Paracetamol (Intranasal Paracetamol) — Bezmialem Vakif University. Intranasal paracetamol inhibits cyclooxygenase enzymes in the central nervous system to reduce pain and fever perception.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Intranasal Paracetamol TARGET	Intranasal Paracetamol	Bezmialem Vakif University	phase 3	Analgesic and antipyretic (non-NSAID)	Cyclooxygenase (COX) enzymes
Preop acetaminophen IV	Preop acetaminophen IV	AdventHealth	marketed	Analgesic and antipyretic (non-NSAID)	Cyclooxygenase (COX) enzymes
Panadol®	Panadol®	Sinew Pharma Inc.	marketed	Analgesic and antipyretic (non-NSAID)	Cyclooxygenase (COX), primarily in central nervous system

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Analgesic and antipyretic (non-NSAID) class)

AdventHealth · 1 drug in this class
Bezmialem Vakif University · 1 drug in this class
Sinew Pharma Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intranasal Paracetamol — Competitive Intelligence Brief. https://druglandscape.com/ci/intranasal-paracetamol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab